We considered whether BRCA-deficient cases with shorter survival would have fewer mutation-associated neoantigens to drive anti-tumor responses, but there was no difference in neoantigen counts between the STS and LTS groups for both BRCA1 and BRCA2 (P = 0.51 and P = 0.39, respectively; Fig. 4c). This evidence concerns the gene BRCA2 and neoplasm.